GLP-1s appear safe for treating diabetes in pregnancy, but evidence gaps remain
New research to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), and published in The Lancet Obstetrics, Gynaecology & Women's Health shows that the use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs for
<p>New research to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), and published in The Lancet Obstetrics, Gynaecology & Women's Health shows that the use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs for </p>